Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Beam Therapeutics

CRISPR Therapeutics

Exact Sciences

Intellia Therapeutics

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). If you suffered a loss on your Teladoc investments or would like to inquire about potentially pursuing

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teladoc Health, Inc. (TDOC)

Our theme of Out Of Favor Health Care Stocks includes healthcare and pharmaceutical names that are seeing a disconnect between their financial performance and recent stock price returns.

Teladoc, CRISPR: Finally Time To Buy Beaten Down Healthcare Names?

Los Angeles, California--(Newsfile Corp. - June 9, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $1,000,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $TDOC #TDOC--Teladoc Health, Inc. Misses First Quarter Financial Estimates Due to $6.6 Billion Non-Cash Goodwill Impairment Charge to Increased Competition

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Teladoc Health, Inc. (TDOC)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022. SO WHAT: If you purchased Teladoc Health securities during the Class Period you may be entitled to compensat

EQUITY ALERT: Rosen Law Firm Encourages Teladoc Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

Did you lose money on investments in Teladoc Health? If so, please visit Teladoc Health, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.New York, New York--(Newsfile Corp. - June 8, 2022) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on...

TELADOC HEALTH, INC. (TDOC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Teladoc Health, Inc. (TDOC)

Austin Gold Corp

Helbiz

Lithium Americas Corp

Millionaire investors make their moves during the "smart money stage" of the investment cycle. Here are four stocks that fit the bracket.

4 Stocks to Buy That Could Make You a Millionaire

Did you lose money on investments in Teladoc Health? If so, please visit Teladoc Health, Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

TELADOC HEALTH, INC. (NYSE: TDOC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Teladoc Health, Inc. (NYSE: TDOC)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). Teladoc investors have until August 5, 2022 to file a lead plaintiff motion. If you suffered a loss on your Teladoc i

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Teladoc Health, Inc. (TDOC) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). Teladoc investors have until August 5, 2022 to file a lead plaintiff motion. Investors suffering losses on their Teladoc investments are encouraged to contact the Law Offices of Howard G. Smith t

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teladoc Health, Inc. (TDOC) Investors

Telehealth software company Teledoc Health (NYSE: TDOC) stock has collapsed from a post-pandemic high of $308 in Feb 2021 to a recent low of $27.38 in May 2022.

Teladoc Health Stock is Pricing Right

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Teladoc securities between October 28, 2021 and April 27, 2022, both dates inclusive (the “Class Period”). Investo

TELADOC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Teladoc Health, Inc. and Encourages Investors to Contact the Firm

New York, New York--(Newsfile Corp. - June 6, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-04687, is on behalf of a class consisting of all persons and entities other than Defendants that...

Pomerantz Law Firm Announces the Filing of a Class Action Against Teladoc Health, Inc. and Certain Officers - TDOC

Peloton

Shopify

While many stocks suffered from the pandemic's initial economic impact, a handful actually benefited.

Which Pandemic Winners Are Still Worth Investors' Attention?

Fiverr

Garmin

MongoDB

SAP SE

Snowflake

Twilio

These best tech stocks to buy are undervalued and have the potential for massive long-term gains. The post 7 Best Tech Stocks to Buy Amid the Market Turmoil appeared first on InvestorPlace.

7 Best Tech Stocks to Buy Amid the Market Turmoil

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teladoc To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 5, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC).If you suffered losses exceeding $50,000 investing in Teladoc stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDOC.

Teladoc Investor Alert

Bristol-Myers

Moderna

Could these health care stocks be worth jumping on now?

Best Health Care Stocks To Invest In Today? 3 In Focus

ARK CEO says company could soar to new highs. Stock gets underweighted in ETF inflows and redemptions.

Teladoc: Cathie Wood's Conflicting Actions

After digging into the telehealth company's financials, you won't want to book an appointment with TDOC stock. The post Stay Away From Unhealthy Teladoc Stock appeared first on InvestorPlace.

Stay Away From Unhealthy Teladoc Stock

AMC Entertainment

Beyond Meat

Fastly

Fisker Inc

Marvell Technology

Snap

Sluggish operational performance and deteriorating bottom line are adverse catalysts for these battered stocks. BYND, FSR, and AMC stock should be avoided in the next few months.

7 Battered Growth Stocks to Avoid Even at a Discount

I was bullish on TDOC stock at a price roughly four times where it is today. I discuss where I went wrong in my assumptions.

Teladoc Stock: Where I Went Wrong

Okta

Pubmatic

Given time, these innovative companies can put investors on a path to complete financial freedom.

5 Growth Stocks That Can Deliver Transformational Wealth (With Patience)

MercadoLibre

Novocure

A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.

3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?

News for Teladoc Stock (TDOC)